Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 6/20 | 0.41 |
| ▸ | DRD3 | P35462 | 6/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 3/20 | 0.38 |
| ▸ | HTR7 | P34969 | 3/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4978587 | 0.93 | CYP2A6 (0.41) | CYP2A6ALDH1A1CYP2A13TSHRACHE | |
| SCHEMBL597327 | 0.86 | CYP2A6 (0.41) | CYP2A6ALDH1A1CYP2A13TSHRACHE | |
| SCHEMBL30864984 | 0.81 | ACHE (0.46) | ACHEDRD2HTR1AHTR2CHTR2B | |
| SCHEMBL11960179 | 0.81 | DRD2 (0.64) | DRD2DRD3ADRA1A | |
| SCHEMBL11960186 | 0.81 | DRD2 (0.64) | DRD2DRD3ADRA1A | |
| Hydrochloric Acid SCHEMBL28996762 | 0.79 | DRD2 (0.62) | DRD2DRD3ADRA1A | |
| SCHEMBL23980063 | 0.78 | DRD2 (0.40) | CYP2A6ALDH1A1CYP2A13TSHRDRD2 | |
| SCHEMBL13487690 | 0.78 | DRD2 (0.66) | ACHEDRD2DRD3DRD4HTR1A | |
| SCHEMBL16233584 | 0.78 | ADRA2A (0.50) | DRD2DRD3HTR1AHTR7ADRA2A | |
| SCHEMBL16233580 | 0.78 | DRD2 (0.66) | DRD2DRD3HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5189234-A | Dimethyltetralin to dimethylnaphthalene | AMOCO CORPORATION (US) | 1993-02-23 | — | — | US | claimed |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8114997-B2 | N4-acylcytosine nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-RE42015-E1 | N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090176730-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| EP-1569652-A4 | N SP 4 /SP-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | PHARMASSET INC (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | GILEAD PHARMASSET LLC | 2007-04-05 | — | — | US | disclosed |
| US-7105527-B2 | N4-acylcytosine nucleosides for treatment of viral infections | GILEAD PHARMASSET LLC | 2006-09-12 | — | — | US | disclosed |
| US-7091309-B2 | Process for the manufacture of temperature-sensitive polymers | SOLUTIA INC. (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1461041-A4 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD (BB) | 2006-03-29 | — | — | EP | disclosed |
| US-6797193-B2 | Heat transfer fluid comprising mixture of phenylcyclohexane and bicyclohexane | SOLUTIS, INC. | 2004-09-28 | — | — | US | disclosed |
| US-20040162408-A1 | PROCESS FOR THE MANUFACTURE OF TEMPERATURE-SENSITIVE POLYMERS | SOLUTIA INC. (US) | 2004-08-19 | — | — | US | disclosed |
| EP-1379602-A1 | PROCESS FOR THE MANUFACTURE OF TEMPERATURE-SENSITIVE POLYMERS | Solutia Inc. (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | GILEAD PHARMASSET LLC | 2003-09-18 | — | — | US | disclosed |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | PHARMASSET, INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003063771-A2 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | PHARMASSET LTD. (BB) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003051298-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051306-A2 | N4-ACYLCYTOSINE-1,3-DIOXOLANE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
| US-20020165421-A1 | Process for the manufacture of temperature-sensitive polymers | SOLUTIA INC. | 2002-11-07 | — | — | US | disclosed |
| WO-2002083812-A1 | PROCESS FOR THE MANUFACTURE OF TEMPERATURE-SENSITIVE POLYMERS | SOLUTIA INC. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | ENTPD5, DUT, NT5C3B | CYP2A6 1327/4885ALDH1A1 2325/4885CYP2A13 2143/4885 |
| US-20090176730-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, NT5C3B, PNP | CYP2A6 1388/4885ALDH1A1 2300/4885CYP2A13 2308/4885 |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | ENTPD5, CDA, ADA | CYP2A6 1101/4885ALDH1A1 645/4885CYP2A13 707/4885 |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | DERA, DPYD, DHPS | CYP2A6 1024/4885ALDH1A1 14/4885CYP2A13 1000/4885 |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, DUT, NT5C3B | CYP2A6 1296/4885ALDH1A1 2341/4885CYP2A13 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.